Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-0.65% $32.31
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 4 694.42 mill |
EPS: | -1.810 |
P/E: | -17.85 |
Earnings Date: | May 12, 2024 |
SharesOutstanding: | 145.29 mill |
Avg Daily Volume: | 1.268 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -17.85 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-3.04x |
Company: PE -17.85 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$3.05 (-90.56%) $-29.26 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 30.53 - 34.09 ( +/- 5.51%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-22 | Barnett Eva Renee | Sell | 2 930 | Common Stock |
2024-02-22 | Levine Mark S. | Sell | 2 134 | Common Stock |
2024-02-22 | Macias William L. | Sell | 2 221 | Common Stock |
2024-02-22 | Butchko Julia G. | Sell | 2 146 | Common Stock |
2024-02-22 | Salzmann Peter | Sell | 13 454 | Common Stock |
INSIDER POWER |
---|
82.85 |
Last 99 transactions |
Buy: 8 040 481 | Sell: 739 102 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $32.31 (-0.65% ) |
Volume | 1.182 mill |
Avg. Vol. | 1.268 mill |
% of Avg. Vol | 93.22 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $35.22 | N/A | Active |
---|
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.